Combined effort of six European universities, the ENVISION_2027 Erasmus+ project had its final meeting in Turku on 30 May–1 June. The project focused on digital education in bioscience studies, addressing both the current need of transitioning from conventional classroom teaching into digital remote teaching, as well as improving the current status of online teaching and e-learning course modules across Europe.
The first Turku Imaging Day will take place in Turku on October 3rd. The day will bring together the imaging community of Turku's universities, which may be unexpectedly large. "Almost 100% of researchers in life sciences use imaging in their work," says Research Manager Pasi Kankaanpää of the Turku Faculty of Medicine.
Registration to BioCity Symposium is open until 11 August 2023. BioCity Symposium is one of the most important meetings in Turku region for researchers working in the fields of bio- and molecular medicine. This year the event is arranged with title Sculpting tissues – Cells, matrix and forces.
Folate-based radiopharmaceuticals can be used in positron emission tomography (PET) imaging to detect folate receptors in brain tumours. The discovery of folate receptors and their exploitation potential with respect to brain tumours is a new and significant finding in the field.
Researchers from Turku Bioscience Centre and InFLAMES Flagship at the University of Turku in Finland, have identified a gene expression signature that can predict the progression of type 1 diabetes.
Docent Pekka Postila and Professor Olli Pentikäinen from the Institute of Biomedicine and InFLAMES Flagship have received 100,000 dollars in funding from the SynGAP Research Fund (SRF) for SynGAP syndrome research.
The Faculty of Medicine at the University of Turku is organising a ceremonial conferment of doctoral degrees on 26 May 2023. The Conferment Ceremony starts at noon at the Turku Concert Hall. The Academic Procession to the Cathedral can be followed starting from 3.30pm (if weather permits).
Through immunotherapies utilising Immune Checkpoint Blockers (ICB), advanced solid cancers can today be treated with unprecedented efficacy. However, not all patients respond positively to these treatments. InFLAMES researcher, Docent Carlos Rogerio Figueiredo and his team are working to uncover the underlying causes of this resistance to ICB. They focus on patients suffering from malignant melanomas and lung cancers as main research models.